|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BCL2L10 |
Gene summary for BCL2L10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BCL2L10 | Gene ID | 10017 |
| Gene name | BCL2 like 10 | |
| Gene Alias | BCL-B | |
| Cytomap | 15q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | H0YMD5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10017 | BCL2L10 | P4T-E | Human | Esophagus | ESCC | 8.71e-14 | 3.06e-01 | 0.1323 |
| 10017 | BCL2L10 | P9T-E | Human | Esophagus | ESCC | 9.29e-04 | 1.26e-01 | 0.1131 |
| 10017 | BCL2L10 | P15T-E | Human | Esophagus | ESCC | 1.28e-03 | 1.13e-01 | 0.1149 |
| 10017 | BCL2L10 | P20T-E | Human | Esophagus | ESCC | 3.13e-11 | 2.58e-01 | 0.1124 |
| 10017 | BCL2L10 | P21T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.14e-01 | 0.1617 |
| 10017 | BCL2L10 | P23T-E | Human | Esophagus | ESCC | 2.58e-03 | 1.39e-01 | 0.108 |
| 10017 | BCL2L10 | P24T-E | Human | Esophagus | ESCC | 9.20e-06 | 1.72e-01 | 0.1287 |
| 10017 | BCL2L10 | P28T-E | Human | Esophagus | ESCC | 4.41e-07 | 1.38e-01 | 0.1149 |
| 10017 | BCL2L10 | P31T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.90e-01 | 0.1251 |
| 10017 | BCL2L10 | P37T-E | Human | Esophagus | ESCC | 1.03e-05 | 1.94e-01 | 0.1371 |
| 10017 | BCL2L10 | P49T-E | Human | Esophagus | ESCC | 3.34e-07 | 8.89e-01 | 0.1768 |
| 10017 | BCL2L10 | P74T-E | Human | Esophagus | ESCC | 1.36e-11 | 2.48e-01 | 0.1479 |
| 10017 | BCL2L10 | P82T-E | Human | Esophagus | ESCC | 7.46e-03 | 1.58e-01 | 0.1072 |
| 10017 | BCL2L10 | P89T-E | Human | Esophagus | ESCC | 3.33e-04 | 2.63e-01 | 0.1752 |
| 10017 | BCL2L10 | P107T-E | Human | Esophagus | ESCC | 1.35e-08 | 1.54e-01 | 0.171 |
| 10017 | BCL2L10 | P127T-E | Human | Esophagus | ESCC | 5.70e-11 | 1.55e-01 | 0.0826 |
| 10017 | BCL2L10 | P128T-E | Human | Esophagus | ESCC | 1.74e-02 | 1.49e-01 | 0.1241 |
| 10017 | BCL2L10 | P130T-E | Human | Esophagus | ESCC | 1.51e-64 | 1.27e+00 | 0.1676 |
| 10017 | BCL2L10 | S014 | Human | Liver | HCC | 7.56e-23 | 1.12e+00 | 0.2254 |
| 10017 | BCL2L10 | S015 | Human | Liver | HCC | 2.19e-27 | 1.24e+00 | 0.2375 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
| GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
| GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
| GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
| GO:2001243111 | Esophagus | ESCC | negative regulation of intrinsic apoptotic signaling pathway | 78/8552 | 98/18723 | 5.50e-12 | 2.10e-10 | 78 |
| GO:0008630110 | Esophagus | ESCC | intrinsic apoptotic signaling pathway in response to DNA damage | 78/8552 | 99/18723 | 1.43e-11 | 5.08e-10 | 78 |
| GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
| GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
| GO:0010952111 | Esophagus | ESCC | positive regulation of peptidase activity | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
| GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
| GO:0010950111 | Esophagus | ESCC | positive regulation of endopeptidase activity | 116/8552 | 179/18723 | 1.77e-07 | 2.79e-06 | 116 |
| GO:00380347 | Esophagus | ESCC | signal transduction in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
| GO:00971927 | Esophagus | ESCC | extrinsic apoptotic signaling pathway in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
| GO:0043280110 | Esophagus | ESCC | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 84/8552 | 129/18723 | 6.38e-06 | 6.55e-05 | 84 |
| GO:2001056110 | Esophagus | ESCC | positive regulation of cysteine-type endopeptidase activity | 94/8552 | 148/18723 | 8.87e-06 | 8.59e-05 | 94 |
| GO:000691915 | Esophagus | ESCC | activation of cysteine-type endopeptidase activity involved in apoptotic process | 54/8552 | 78/18723 | 2.17e-05 | 1.87e-04 | 54 |
| GO:200123322 | Liver | HCC | regulation of apoptotic signaling pathway | 226/7958 | 356/18723 | 7.26e-16 | 5.68e-14 | 226 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BCL2L10 | SNV | Missense_Mutation | novel | c.709N>A | p.Leu237Ile | p.L237I | protein_coding | possibly_damaging(0.578) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | ||
| BCL2L10 | SNV | Missense_Mutation | novel | c.177N>G | p.Ile59Met | p.I59M | protein_coding | tolerated(0.24) | benign(0.052) | TCGA-AA-3529-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| BCL2L10 | SNV | Missense_Mutation | c.235G>A | p.Ala79Thr | p.A79T | protein_coding | tolerated(0.2) | benign(0.047) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| BCL2L10 | insertion | Frame_Shift_Ins | novel | c.569_570insAGTTG | p.Ser191ValfsTer40 | p.S191Vfs*40 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| BCL2L10 | SNV | Missense_Mutation | novel | c.679N>T | p.Ile227Phe | p.I227F | protein_coding | benign(0.412) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| BCL2L10 | SNV | Missense_Mutation | novel | c.679N>T | p.Ile227Phe | p.I227F | protein_coding | benign(0.412) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| BCL2L10 | SNV | Missense_Mutation | rs142737063 | c.589C>A | p.Leu197Ile | p.L197I | protein_coding | possibly_damaging(0.578) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
| BCL2L10 | SNV | Missense_Mutation | c.192N>A | p.Phe64Leu | p.F64L | protein_coding | tolerated(0.31) | probably_damaging(0.969) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| BCL2L10 | SNV | Missense_Mutation | novel | c.695N>T | p.Thr232Ile | p.T232I | protein_coding | benign(0) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| BCL2L10 | SNV | Missense_Mutation | c.233N>C | p.Val78Ala | p.V78A | protein_coding | tolerated(0.09) | benign(0.043) | TCGA-MP-A4T6-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10017 | BCL2L10 | DRUGGABLE GENOME | inhibitor | CHEMBL2107358 | OBATOCLAX MESYLATE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |